EyePoint Pharmaceuticals, Inc. (EYPT) has a negative trailing P/E of -5.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 13.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -19.86%, forward earnings yield 7.59%. PEG 0.08 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 49/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -4.2 | 0.01 | 4.29 | 55.24 | - |
| 2017 | -3.3 | 0.14 | 4.53 | 8.02 | - |
| 2018 | -1.8 | -0.02 | 8.23 | 32.47 | - |
| 2019 | -2.8 | 0.06 | 19.41 | 7.94 | - |
| 2020 | -1.9 | 0.04 | 4.56 | 2.45 | - |
| 2021 | -6.0 | 0.14 | 1.91 | 9.53 | - |
| 2022 | -1.3 | -0.04 | 1.36 | 3.15 | - |
| 2023 | -12.4 | 0.37 | 3.29 | 19.04 | - |
| 2024 | -3.2 | -0.12 | 1.25 | 9.69 | - |
| 2025 | -5.8 | -0.16 | 4.37 | 42.66 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-6.81 | $1.62M | $-21.55M | -1330.1% |
| 2017 | $-5.23 | $7.54M | $-18.49M | -245.2% |
| 2018 | $-11.50 | $2.96M | $-53.17M | -1795.7% |
| 2019 | $-6.04 | $20.37M | $-62.97M | -309.2% |
| 2020 | $-4.10 | $34.44M | $-52.65M | -152.9% |
| 2021 | $-2.22 | $36.94M | $-63.92M | -173% |
| 2022 | $-3.34 | $41.4M | $-124.51M | -300.7% |
| 2023 | $-1.82 | $46.02M | $-70.8M | -153.8% |
| 2024 | $-2.32 | $43.27M | $-130.87M | -302.4% |
| 2025 | $-3.17 | $31.37M | $-231.96M | -739.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.21 | $-3.59 – $-2.50 | $1.13M | $715.74K – $1.55M | 9 |
| 2027 | $-3.49 | $-4.42 – $-2.53 | $51.81M | $19.31M – $84.3M | 7 |
| 2028 | $-0.99 | $-2.13 – $0.30 | $286.89M | $273.89M – $299.89M | 7 |
| 2029 | $1.09 | $0.21 – $1.97 | $571.25M | $215.05M – $927.46M | 2 |
| 2030 | $2.91 | $0.55 – $5.27 | $861.22M | $324.2M – $1.4B | 5 |
